Showing results (351-360 of 378) with videos related to

Sort By:
Pageof 38
Trials|September 6, 2022
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials unitsSharon B Love, Fay Cafferty, Claire Snowdon, et al.
Cancer Cell|November 22, 2024
Elucidating acquired PARP inhibitor resistance in advanced prostate cancerGeorge Seed, Nick Beije, Wei Yuan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 11, 2025
oDigital pathology biomarkers for guiding radiotherapy-based treatment concepts in prostate cancer - a systematic review and expert consensusConstantinos Zamboglou, William De Doncker, Andreas Thomas Christoforou, et al.
Lancet (London, England)|December 26, 2021
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocolGerhardt Attard, Laura Murphy, Noel W Clarke, et al.
Lancet (London, England)|January 1, 2016
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D James, Matthew R Sydes, Noel W Clarke, et al.
The New England Journal of Medicine|June 6, 2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNicholas D James, Johann S de Bono, Melissa R Spears, et al.
Lancet (London, England)|October 26, 2018
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trialChristopher C Parker, Nicholas D James, Christopher D Brawley, et al.
European Urology Oncology|June 4, 2019
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectivenessBeth S Woods, Eleftherios Sideris, Matthew R Sydes, et al.
Bladder Cancer (Amsterdam, Netherlands)|March 4, 2025
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancerAndrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, et al.
JNCI Cancer Spectrum|October 20, 2023
Large-scale meta-genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer typesElnaz Naderi, Miguel E Aguado-Barrera, Line M H Schack, et al.
Pageof 38